Some prognostic factors for GBM have been identified, of which isocitrate dehydrogenase 1 (IDH1) mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation have been widely used in clinical practice (3). This evidence concerns the gene IDH1 and glioblastoma.